全文获取类型
收费全文 | 130981篇 |
免费 | 9991篇 |
国内免费 | 3266篇 |
专业分类
耳鼻咽喉 | 1313篇 |
儿科学 | 7285篇 |
妇产科学 | 3811篇 |
基础医学 | 14528篇 |
口腔科学 | 1692篇 |
临床医学 | 13721篇 |
内科学 | 21323篇 |
皮肤病学 | 2477篇 |
神经病学 | 11468篇 |
特种医学 | 2874篇 |
外国民族医学 | 3篇 |
外科学 | 11347篇 |
综合类 | 18021篇 |
现状与发展 | 15篇 |
预防医学 | 7657篇 |
眼科学 | 6116篇 |
药学 | 7187篇 |
58篇 | |
中国医学 | 11484篇 |
肿瘤学 | 1858篇 |
出版年
2024年 | 413篇 |
2023年 | 2358篇 |
2022年 | 4859篇 |
2021年 | 6417篇 |
2020年 | 5804篇 |
2019年 | 4549篇 |
2018年 | 4651篇 |
2017年 | 4807篇 |
2016年 | 4883篇 |
2015年 | 4639篇 |
2014年 | 8866篇 |
2013年 | 9352篇 |
2012年 | 7300篇 |
2011年 | 8423篇 |
2010年 | 6560篇 |
2009年 | 6348篇 |
2008年 | 6189篇 |
2007年 | 6270篇 |
2006年 | 5703篇 |
2005年 | 4736篇 |
2004年 | 4043篇 |
2003年 | 3559篇 |
2002年 | 2519篇 |
2001年 | 2276篇 |
2000年 | 1967篇 |
1999年 | 1789篇 |
1998年 | 1504篇 |
1997年 | 1413篇 |
1996年 | 1337篇 |
1995年 | 1275篇 |
1994年 | 1084篇 |
1993年 | 959篇 |
1992年 | 886篇 |
1991年 | 686篇 |
1990年 | 637篇 |
1989年 | 546篇 |
1988年 | 533篇 |
1987年 | 485篇 |
1986年 | 424篇 |
1985年 | 571篇 |
1984年 | 473篇 |
1983年 | 307篇 |
1982年 | 391篇 |
1981年 | 364篇 |
1980年 | 288篇 |
1979年 | 232篇 |
1978年 | 151篇 |
1977年 | 113篇 |
1976年 | 96篇 |
1975年 | 41篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
B Maybury A Powell-Chandler N Kumar 《Annals of the Royal College of Surgeons of England》2015,97(3):e37-e38
We report two British cases of liver abscess, due to Klebsiella pneumoniae and associated with synchronous infection elsewhere, which required liver resection for definitive treatment. They illustrate the geographic spread of aggressive K pneumoniae liver infection and demonstrate the importance of early aggressive treatment. 相似文献
2.
Hyun Jong Choi Jong Ho Moon Yun Nah Lee Hyun Su Kim Ji Su Ha Tae Hoon Lee Sang‐Woo Cha Young Deok Cho Sang‐Heum Park 《Digestive endoscopy》2015,27(7):772-775
Direct peroral cholangioscopy (POC) using an ultra‐slim upper endoscope is one modality of POC for intraductal endoscopic evaluation and treatment of the bile duct. Choledochoduodenostomy (CDS) is one modality of biliary bypass surgery that provides a new route to the bile duct. We carried out direct POC using an ultra‐slim upper endoscope without the use of accessories in 10 patients (four sump syndromes, three bile duct strictures and three intrahepatic duct stones) previously undergoing surgical CDS. Direct POC was successful in all patients. The use of an intraductal balloon catheter was required in one patient for advancement of the endoscope into the bile duct. Distal bile ducts with sump syndromes were cleared using baskets and water irrigation under direct POC. Cholangiocarcinoma was diagnosed in one patient with hilar bile duct stricture after cholangioscopic evaluation and a targeting forceps biopsy under direct POC. Intrahepatic duct stones were successfully extracted after intraductal fragmentation under direct POC. Oozing bleeding occurred during intraductal lithotripsy but stopped spontaneously. Direct POC using an ultra‐slim upper endoscope without the assistance of accessories can easily be carried out in patients undergoing CDS. 相似文献
3.
盛文燕 《浙江中西医结合杂志》2015,25(11)
<正>我国结核患者在2011年统计已达500万例,仅次于印度位居世界第二[1]。临床多见抗结核药物引起肝损害及过敏反应,对眼部的副反应关注较少[2]。笔者临床中发现部分结核患者在抗结核治疗早期可出现视物模糊、异物感、干涩及视物不持久等类似干眼的主诉,眼科常规检查未发现明显视神经病变,更多为眼表的改变。笔者观察抗结核药物对眼表的毒副反应,报道如下。1资料与方法1.1研究对象收集2012年1月—2014年10月 相似文献
4.
《Archives of Cardiovascular Diseases》2022,115(10):505-513
Central illustration: cumulative major adverse cardiac events (MACE) and bioresorbable vascular scaffold (BVS) thrombosis rates after 1, 2, 3, 4 and 5 years. 相似文献
5.
Interstitial cystitis/bladder pain syndrome (IC/BPS) and vulvodynia are chronic pain syndromes that appear to be intertwined from the perspectives of embryology, pathology and epidemiology. These associations may account for similar responses to various therapies. 相似文献
6.
2015年中华医学会感染病学分会艾滋病学组发布了第三版《艾滋病诊疗指南》。新版指南强调抗病毒治疗时点前移:一旦成人确诊感染人类免疫缺陷病毒(HIV), 若无禁忌宜尽早启动抗HIV治疗。对于合并机会性感染的HIV感染者, 在感染控制、病情稳定后也应及早开始抗病毒治疗。尤其强调HIV合并结核患者在CD4阳性淋巴细胞数少于200/μL的情况下, 建议抗结核两周内即开始抗病毒治疗。在抗HIV治疗用药中, 淘汰了一些毒副作用大、依从性较差的药物, 如司他夫定、去羟肌苷、茚地那韦等, 优选抗病毒效力强、服药方便的组合, 如拉米夫定、替诺福韦、依非韦伦组合。对于HIV感染的婴幼儿, 亦主张及早抗HIV治疗。对于五岁以内的幼儿, 主张确诊后即启动抗病毒治疗。对于HIV感染的孕产妇, 建议尽快予以全程、联合抗HIV治疗, 寓防于治。 相似文献
7.
Benyam Kinde Harrison W. Gabel Caitlin S. Gilbert Eric C. Griffith Michael E. Greenberg 《Proceedings of the National Academy of Sciences of the United States of America》2015,112(22):6800-6806
DNA methylation at CpG dinucleotides is an important epigenetic regulator common to virtually all mammalian cell types, but recent evidence indicates that during early postnatal development neuronal genomes also accumulate uniquely high levels of two alternative forms of methylation, non-CpG methylation and hydroxymethylation. Here we discuss the distinct landscape of DNA methylation in neurons, how it is established, and how it might affect the binding and function of protein readers of DNA methylation. We review studies of one critical reader of DNA methylation in the brain, the Rett syndrome protein methyl CpG-binding protein 2 (MeCP2), and discuss how differential binding affinity of MeCP2 for non-CpG and hydroxymethylation may affect the function of this methyl-binding protein in the nervous system. 相似文献
8.
Edward J. Holland Walter O. Whitley Kenneth Sall Stephen S. Lane Aparna Raychaudhuri Steven Y. Zhang 《Current medical research and opinion》2016,32(10):1759-1765
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED. 相似文献
9.
10.